This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
When I was a student in pharmacy school, one of our earliest assignments was the so-called 'JellyBean Experiment,' whereby students were assigned a longitudinal project in which they were to mimic a patient with a chronic condition treated with medications. The assignment is aimed to help students understand the pill burden that patients face on a daily basis, and in my mind, bring in a better empathetic understanding towards nonadherence and how to talk about it.
Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend. On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry exper
What to do with antiplatelet medications in the setting of anemia has always been a huge challenge for me. Here’s a scenario with some questions to think about. A 64 year old female has a history of CAD, hyperlipidemia, hypertension, CABG, depression, anemia, osteoarthritis, and constipation. Current meds include: Lisinopril 5 mg daily Clopidogrel 75 […].
Assessment of medication and goals of therapy need to be continually monitored. In this scenario, I pick out a few medications that should be looked in consideration of age and goals of reducing medication burden. A 98 year old female is on the following medications. Lipitor 10 mg daily Amlodipine 10 mg daily Diovan/HCTZ 160/12.5 […]. The post Reducing Medication Burden – Age and Goals of Therapy are Important appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content